Literature DB >> 22967965

Outcome of patients with early stage oral cancer managed by an observation strategy towards the N0 neck using ultrasound guided fine needle aspiration cytology: No survival difference as compared to elective neck dissection.

Géke B Flach1, Mark Tenhagen, Remco de Bree, Ruud H Brakenhoff, Isaac van der Waal, Elisabeth Bloemena, Dirk J Kuik, Jonas A Castelijns, C René Leemans.   

Abstract

OBJECTIVES: Management of the clinically N0 neck in oral cancer patients remains controversial. We describe the outcome of patients with T1-T2 oral cancer and N0 neck based on ultrasound guided fine needle aspiration cytology (USgFNAC) who were treated by transoral excision and followed by a 'wait and scan' policy (W&S). PATIENTS AND METHODS: This retrospective analysis included 285 consecutive patients of whom 234 were followed by W&S and 51 underwent elective neck dissection (END). Survival rates were compared between groups and correction for confounding factors was performed.
RESULTS: Of W&S patients, the 5-year disease-specific (DSS) and overall survival (OS) were 94.2% and 81.6% respectively. During follow-up 72.2% remained free of lymph node metastases and 27.8% developed delayed metastases. W&S patients with delayed metastases had a 5-year DSS and OS of 80.0% and 62.8%, respectively. In patients with positive END these rates were 81.3% and 64.2%, respectively. Between the groups, survival rates were not significantly different. Of the W&S patients with delayed metastases, 90.6% needed adjuvant radiotherapy versus 55.0% of patients with positive END.
CONCLUSION: With regard to survival, in patients with early stage oral cancer and cN0 neck a 'wait and scan' policy using strict USgFNAC surveillance is justified as survival is not negatively influenced. Using a 'wait and scan' follow-up strategy instead of elective neck treatment, unnecessary neck dissection and its accompanying morbidity can be avoided in 72.2% of patients. However, for the small proportion of patients with delayed metastases, more extensive treatment with adjuvant radiotherapy is needed.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22967965     DOI: 10.1016/j.oraloncology.2012.08.006

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  14 in total

Review 1.  Outcome after elective neck dissection and observation for the treatment of the clinically node-negative neck (cN0) in squamous cell carcinoma of the oropharynx.

Authors:  R Böscke; B D Cakir; A S Hoffmann; S Wiegand; J Quetz; J E Meyer
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-05-10       Impact factor: 2.503

2.  Variation in treatment and outcome in the early stage oral cavity squamous cell carcinoma.

Authors:  Darragh S Gogarty; Paul Lennon; Sandra Deady; J Barry O'Sullivan; Orla McArdle; Mary Leader; Patrick Sheahan; James Paul O'Neill
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-08-23       Impact factor: 2.503

3.  [68Ga]Ga-tilmanocept PET/CT lymphoscintigraphy: a novel technique for sentinel lymph node imaging.

Authors:  Rutger Mahieu; Gerard C Krijger; F F Tessa Ververs; Remmert de Roos; Remco de Bree; Bart de Keizer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-04       Impact factor: 9.236

4.  Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline.

Authors:  Shlomo A Koyfman; Nofisat Ismaila; Doug Crook; Anil D'Cruz; Cristina P Rodriguez; David J Sher; Damian Silbermins; Erich M Sturgis; Terance T Tsue; Jared Weiss; Sue S Yom; F Christopher Holsinger
Journal:  J Clin Oncol       Date:  2019-02-27       Impact factor: 44.544

5.  Predictive Significance of Tumor Depth and Budding for Late Lymph Node Metastases in Patients with Clinical N0 Early Oral Tongue Carcinoma.

Authors:  Yukiko Hori; Akira Kubota; Tomoyuki Yokose; Madoka Furukawa; Takeshi Matsushita; Morihito Takita; Sachiyo Mitsunaga; Nobutaka Mizoguchi; Tetsuo Nonaka; Yuko Nakayama; Nobuhiko Oridate
Journal:  Head Neck Pathol       Date:  2017-04-03

6.  Within-patient comparison between [68Ga]Ga-tilmanocept PET/CT lymphoscintigraphy and [99mTc]Tc-tilmanocept lymphoscintigraphy for sentinel lymph node detection in oral cancer: a pilot study.

Authors:  Rutger Mahieu; Dominique N V Donders; Gerard C Krijger; F F Tessa Ververs; Remmert de Roos; John L M M Bemelmans; Rob van Rooij; Remco de Bree; Bart de Keizer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-12-28       Impact factor: 10.057

7.  Neck observation versus elective neck dissection in management of clinical T1/2N0 oral squamous cell carcinoma: a retrospective study of 232 patients.

Authors:  Xiangqi Liu; Xiaomei Lao; Lizhong Liang; Sien Zhang; Kan Li; Guiqing Liao; Yujie Liang
Journal:  Chin J Cancer Res       Date:  2017-06       Impact factor: 5.087

Review 8.  Current philosophy in the surgical management of neck metastases for head and neck squamous cell carcinoma.

Authors:  H Hakan Coskun; Jesus E Medina; K Thomas Robbins; Carl E Silver; Primož Strojan; Afshin Teymoortash; Phillip K Pellitteri; Juan P Rodrigo; Sandro J Stoeckli; Ashok R Shaha; Carlos Suárez; Dana M Hartl; Remco de Bree; Robert P Takes; Marc Hamoir; Karen T Pitman; Alessandra Rinaldo; Alfio Ferlito
Journal:  Head Neck       Date:  2014-06-30       Impact factor: 3.147

9.  Applicability of preoperative nuclear morphometry to evaluating risk for cervical lymph node metastasis in oral squamous cell carcinoma.

Authors:  Masaaki Karino; Eiji Nakatani; Katsumi Hideshima; Yoshiki Nariai; Kohji Tsunematsu; Koichiro Ohira; Takahiro Kanno; Izumi Asahina; Tatsuo Kagimura; Joji Sekine
Journal:  PLoS One       Date:  2014-12-30       Impact factor: 3.240

10.  The Effect of Radiotherapy on Ultrasound-Guided Fine Needle Aspiration Biopsy and the Ultrasound Characteristics of Neck Lymph Nodes in Oral Cancer Patients after Primary Treatment.

Authors:  Wu-Chia Lo; Po-Wen Cheng; Chi-Te Wang; Pei-Wei Shueng; Chen-Hsi Hsieh; Yih-Leong Chang; Li-Jen Liao
Journal:  PLoS One       Date:  2016-03-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.